ArticleGynecologic oncology reports2020

Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).

Alessandro D Santin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.